CYP1B1 and nonpapillary renal cell carcinoma: Taken together, these findings indicate that CYP1B1 is a potential therapeutic target for treating ccRCC and that PCD-1 in combination with sunitinib synergistically attenuate acquired sunitinib resistance (Fig. 8).